Compare Aurobindo Pharma with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SANOFI INDIA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SANOFI INDIA AUROBINDO PHARMA/
SANOFI INDIA
 
P/E (TTM) x 16.0 44.2 36.3% View Chart
P/BV x 3.3 8.1 40.5% View Chart
Dividend Yield % 0.3 1.1 29.8%  

Financials

 AUROBINDO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
SANOFI INDIA
Dec-18
AUROBINDO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8306,840 12.1%   
Low Rs5274,630 11.4%   
Sales per share (Unadj.) Rs333.91,203.1 27.8%  
Earnings per share (Unadj.) Rs40.4165.3 24.4%  
Cash flow per share (Unadj.) Rs51.8209.9 24.7%  
Dividends per share (Unadj.) Rs2.5084.00 3.0%  
Dividend yield (eoy) %0.41.5 25.2%  
Book value per share (Unadj.) Rs237.1963.6 24.6%  
Shares outstanding (eoy) m585.9123.03 2,544.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.8 42.6%   
Avg P/E ratio x16.834.7 48.5%  
P/CF ratio (eoy) x13.127.3 48.0%  
Price / Book Value ratio x2.96.0 48.1%  
Dividend payout %6.250.8 12.2%   
Avg Mkt Cap Rs m397,569132,078 301.0%   
No. of employees `00017.93.3 540.9%   
Total wages/salary Rs m25,8494,068 635.4%   
Avg. sales/employee Rs Th10,956.98,393.8 130.5%   
Avg. wages/employee Rs Th1,447.71,232.4 117.5%   
Avg. net profit/employee Rs Th1,324.31,153.0 114.9%   
INCOME DATA
Net Sales Rs m195,63627,708 706.1%  
Other income Rs m1,553897 173.2%   
Total revenues Rs m197,18928,605 689.4%   
Gross profit Rs m39,5196,235 633.8%  
Depreciation Rs m6,6801,027 650.4%   
Interest Rs m2,6267 37,514.3%   
Profit before tax Rs m31,7676,098 520.9%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2692,292 317.1%   
Profit after tax Rs m23,6453,806 621.3%  
Gross profit margin %20.222.5 89.8%  
Effective tax rate %22.937.6 60.9%   
Net profit margin %12.113.7 88.0%  
BALANCE SHEET DATA
Current assets Rs m153,64515,922 965.0%   
Current liabilities Rs m120,4296,235 1,931.5%   
Net working cap to sales %17.035.0 48.6%  
Current ratio x1.32.6 50.0%  
Inventory Days Days13564 212.4%  
Debtors Days Days6421 305.2%  
Net fixed assets Rs m103,9097,539 1,378.3%   
Share capital Rs m586230 254.7%   
"Free" reserves Rs m138,32221,962 629.8%   
Net worth Rs m138,90822,192 625.9%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54429,839 886.6%  
Interest coverage x13.1872.1 1.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.9 79.6%   
Return on assets %9.912.8 77.7%  
Return on equity %17.017.2 99.3%  
Return on capital %23.827.5 86.6%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,741NA-   
Fx inflow Rs m97,3167,587 1,282.7%   
Fx outflow Rs m40,5897,145 568.1%   
Net fx Rs m56,727442 12,834.2%   
CASH FLOW
From Operations Rs m16,2203,739 433.8%  
From Investments Rs m-28,768-731 3,935.5%  
From Financial Activity Rs m19,191-1,972 -973.2%  
Net Cashflow Rs m6,6561,036 642.5%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 8.0 14.4 55.2%  
FIIs % 27.7 14.6 189.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.5 97.1%  
Shareholders   69,601 15,184 458.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DR. REDDYS LAB  STERLING BIOTECH  JUBILANT LIFE SCIENCES  VENUS REMEDIES  IPCA LABS  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 178 Points Higher; Telecom and Power Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest throughout the day today and ended on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Tata Motors Tripled in 18 Months but You Can Do Even Better. Here's How...(Profit Hunter)

Jun 24, 2020

Rahul is ready for a repeat of his famous 2008 Tata Motors call.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 3, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS